Company intelligence / Profile preview
EnnovaBio
Shanghai, Shanghai, Chinaennovabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
EnnovaBio has advanced at least one program into Phase 2 clinical trials for acute kidney injury. Other programs have reached IND approval stages for psoriasis and ulcerative colitis. The company leverages informatics-driven drug discovery with a focus on small molecules modulating immune checkpoints and other disease-relevant targets. Clinical results are not yet widely published or available in detail[2][7].
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic DisordersNephrologyImmunologyDermatologyHematologyOncologyInfectious Diseases
- Modalities
- Small moleculesiRNA (Small interfering RNA)Chemical drugs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Not publicly disclosed; no major pharmaceutical partnerships identified from available data.
Beyond the preview
Go deeper on EnnovaBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EnnovaBio.